p53 Review Article

You have free access to this content

TP53 family members and human cancers†

  1. Jean Bénard1,2,*,
  2. Setha Douc-Rasy2,
  3. Jean-Charles Ahomadegbe1,3,4

Article first published online: 24 FEB 2003

DOI: 10.1002/humu.10172

Issue

Human Mutation

Human Mutation

Special Issue: Focus on p53 and Cancer

Volume 21, Issue 3, pages 182–191, March 2003

Additional Information

How to Cite

Bénard, J., Douc-Rasy, S. and Ahomadegbe, J.-C. (2003), TP53 family members and human cancers. Hum. Mutat., 21: 182–191. doi: 10.1002/humu.10172

Author Information

  1. 1

    Unité de Génétique Tumorale, Service de Génétique, Département de Biologie Clinique, Institut Gustave Roussy, Villejuif, France

  2. 2

    Centre National de la Recherche Scientifique UMR8126, Institut Gustave Roussy, Villejuif, France

  3. 3

    UPRESS Pharmacologie et Nouveaux Traitements des Cancers, Institut Gustave Roussy, Villejuif, France

  4. 4

    Faculté de Pharmacie, UPJV, Amiens, France

*Unité de Génétique Tumorale, Service de Génétique, Departement de Biologie Clinique, Institut Gustave Roussy, Villejuif, France

  1. †

    For the p53 Special Issue

Publication History

  1. Issue published online: 24 FEB 2003
  2. Article first published online: 24 FEB 2003

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (179K)

REFERENCES

  • Ahomadegbe JC, Tourpin S, Kaghad M, Zelek L, Vayssade M, Mathieu MC, Rochard F, Spielmann M, Tursz T, Caput D, Riou G, Bénard J. 2000. Loss of heterozygosity, allele silencing and decreased expression of p73 gene in breast cancers: prevalence of alterations in inflammatory breast cancers. Oncogene 19:5413–5418.
  • Allart S, Martin H, Detraves C, Terrasson J, Caput D, Davrinche C. 2002. Human cytomegalovirus induces drug resistance and alteration of programmed cell death by accumulation of ΔN-p73 alpha. J Bioe Chem 277:29063–29068.
  • Balint E, Bates S, Vousden KH. 1999. Mdm-2 p73α without targeting degradation. Oncogene 18:3923–3929.
  • Barrois M, Eychenne MK, Terrier-Lacombe MJ, Duarte N, Dubourg C, Douc-Rasy S, Chompret A, Khagad M, Hartmann O, Caput D, Bénard J. 2001. Genomic and allelic expression status of the p73 gene in human neuroblastoma. Med Pediatr Oncol 36:45–48.
    Direct Link:
  • Casciano I, Mazzocco K, Boni L, Pagnan G, Banelli B, Allemanni G, Ponzoni M, Tonini GP, Romani M. 2002a. Expression of ΔNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ 9:246–251.
  • Casciano I, Banelli B, Croce M, Allemanni G, Ferrini S, Tonini GP, Ponzoni M, Romani M. 2002b. Epigenetic control of transcription of the anti-apoptotic ΔN variant of the p73 gene in neuroblastoma. Cell Death Differ 9:343–345.
  • Celli J, Duijf P, Hamel BC, Bamshad M, Kramer B, Smits AP, Newbury-Ecob R, Hennekam RC, Van Buggenhout G, van Haeringen A, Woods CG, van Essen AJ, de Waal R, Vriend G, Haber DA, Yang A, McKeon F, Brunner HG, van Bokhoven H. 1999. Heteozygous germlin mutations in the p53 homolog p63 are the cause of EEC syndrome. Cell 99:143–153.
  • Crook T, Nicholls JM, Brooks L, O'Nions J, Allday MJ. 2000. High level expression of Δ-N-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC). Oncogene 19:3439–3444.
  • Curtin JC, Dragnev KH, Sekul D, Christie AJ, Dmitrovsky E, Spinella MJ. 2001. Retinoic acid activates p53 in human embryonal carcinoma through retinoid receptor-dependent stimulation of p53 transactivation function. Oncogene 20:2559–2569.
  • De Laurenzi V, Costanzo A, Barcaroli D, Rerrinoni A, Falco M, Annicchiarico-Petruzzelli M, Levrero M, Melino G. 1998. Two new p73 splice variants gamma and delta, with different transcriptional activity. J Exp Med 188:1763–1768.
  • De Laurenzi V, Raschella G, Barcaroli D, Annicchiarico-Petruzelli M, Ranalli M, Catani M, Tanno B, Costanzo A, Levrero M, Melino G. 2000. Induction of neuronal differentiation by p73 in a neuroblastoma cell line. J Biop Chem 275:15226–15231.
  • Dohn M, Zhang S, Chen X. 2001. p63alpha and DeltaNp63alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. Oncogene 20:3193–3205.
  • Dominguez G, Silva JM, Silva J, Garcia JM, Sanchez A, Navarro A, Gallego I, Provencio M, Espana P, Bonilla F. 2001. Wild type p73 overexpression and high-grade malignancy in breast cancer. Breast Cancer Res 66:183–190.
  • Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Jr., Butel JS, Bradley A. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumor. Nature 356:215–221.
  • Douc-Rasy S, Barrois M, Echeynne M, Kaghad M, Blanc E, Raguenez G, Goldschneider D, Terrier-Lacombe MJ, Hartmann O, Moll U, Caput D, Bénard J. 2002. ΔN-p73α accumulates in human neuroblastic tumors; Am J Pathol 160:631–639.
  • Faridoni-Laurens L, Bosq J, Janot F, Vayssade M, Le Bihan ML, Kaghad M, Caput D, Bénard J, Ahomadegbe JC. 2001. p73 expression in basal layers of head and neck squamous epithelium: a role in differentiation and carcinogenesis in concert with p53 and p63? Oncogene 20:5302–5312.
  • Fillippovich I, Sorokina N, Gatei M, Haupt Y, Hobson K, Moallem E, Spring K, Mould M, McGuckin MA, Lavin MF, Khanna KK. 2001. Transactivation deficient p73alpha (p73 Deltaexon2) inhibits apoptosis and competes with p53. Oncogene 20:514–522.
  • Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F, Jacks T. 2002. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416:560–564.
  • Gong J, Costanzo A, Yang H, Melino G, Kaelin WG, Levero M, Wang J. 1999. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 399:806–808.
  • Grob TJ, Fey MF, Tobler A. 2002. The two faces of p73. Cell Death Differ 9:237–245.
  • Haupt Y, Maya R, Kazaz A, Oren M. 1997. MDM2 promotes the rapid degradation of p53. Nature 387:296–299.
  • Hibi K, Trink BMP, Westra WH, Caballero OL, Hill DE, Ratovitski EA, Jen J, Sidransky D. 2000. AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci 97:5462–5467.
  • Ishimoto O, Kawahara C, Enjo K, Obinata M, Nukiwa T, Ikawa S. 2001. Possible oncogenic potential of its antagonist ΔNp73: a newly identtified isoform of human p73. Cancer Res 62:636–641.
  • Irwin MS, Kaelin WG. 2001. P53 family update: p73 and p63 develop their own identities. Cell Growth Differ 12:337–349.
  • Jost CA, Marin MC, Kaelin WG. 1997. P73 is a simian (correction of human) p53-related protein that can induce apoptosis. Nature 389:191–194.
  • Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F, Caput D. 1997. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90:809–819.
  • Kartasheva N, Contente A, Lenz-Stöppler C, Roth J, Dobelstein M. 2002. P53 induces the expression p73ΔN, establishing an autoregulatory feedback loop. Oncogene 21:4715–4727.
  • Kovalev S, Marchenko N, Swendeman S, La Quaglia M, Moll U. 1998. Expression level, allelic origin and mutation analysis of the p73 gene in neuroblastoma tumors and cell lines. Cell Growth Differ 9:897–903.
  • Liefer KM, Koster MI, Wang XJ, Yang A, McKeon F, Roop DR. 2000. Down-regulation of p63 is required for epidermal UV-B-induced apoptosis. Cancer Res 60:4016–4020.
  • Lowe S, Ryley H, Jacks T, Houssman D. 1993. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957–967.
  • Melino G, De Laurenzi V, Vousden K. 2002. p73: friend or foe in tumorigenesis? Nature Rev 2:605–615.
  • Meyer G, Perez-Garcia CG, Abraham H, Caput D. 2002. Expression of p73 and reelin in the developing human cortex. J Neurosci 22:4973–4986.
  • Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. 1999. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398:708–713.
  • Minty A, Dumont X, Kaghad M, Caput D. 2000. Covalent modification of p73α by SUMO-1. Two-hybrid screening with p73 identifies novel SUMO-1 interacting proteins and a SUMO-1 interaction motif. J Biol Chem 275:36316–36323.
  • Moll U, LaQuaglia M, Bénard J, Riou G. 1995. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci USA 92:4407–4411.
  • Naka M, Ozaki T, Takada N, Takahashi M, Shishikura T, Sakiyama S, Tada M, Todo S, Nakagawara A. 2001. Functional characterization of naturally occurring mutants (P405R and P425L) of p73 alpha and p73beta found in neuroblastoma and lung cancer. Oncogene 20:3568–3572.
  • Nakagawa T, Takahashi M, Ozaki T, Watanabe KI, Todo S, Mizuguchi H, Hayakawa T, Nakagawara A. 2002. Autoinhibitory regulation of p63 by ΔNp73 to modulate cell survival and death through a p73-specific target element within the ΔNp73 promoter. Mol Cell Biol 22:2575–2585.
  • O'Nions J, Brooks LA, Sullivan A, Bell A, Dunne B, Rozycka M, Reddy A, Tidy JA, Evans D, Farrell PJ, Evans A, Gasco M, Gusterson B, Crook T. 2001. p73 is over-expressed in vulval cancer principally as the Delta 2 isoform. Br J Cancer 85:1551–1556.
  • Ozaki T, Naka M, Takda N, Tada M, Sakiyama S, Nakagawara A. 1999. Deletion of the COOH-terminal region of p73alpha enhances both its transactivation function and DNA-binding activity but inhibits induction of apoptosis in mammalian cells. Cancer Res 58:5902–5907.
  • Park JJ, Sun D, Quade BJ, Flynn C, Sheets EE, Tang A, McKeon F, Crum CP. 2000. Stratified mucin-producing intraepithelial lesions of the cervix: adenosquamous or columnar cell neoplasia? Am J Surg Pathol 24:1414–1419.
  • Patturajan M, Nomoto S, Sommer M, Hibi K, Zangen R, Poliak N, Califano J, Trink B, Ratoviski E, Sidransky D. 2002. ΔNp63 induces β-catenin nuclear accumulation and signaling. Cancer Cell 1:369–379.
  • Pozniak CD, Radinovic S, Yang A, McKeon F, Kaplan DR, Miller FD. 2000. An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science 289:304–306.
  • Rotter V, Aloni-Grinstein R, Schwartz D, Elkind NB, Simons A, Wolkowicz R, Lavigne M, Beserman P, Kapon A, Goldfinger N. 1994. Does wild-type p53 play a role in normal cell differentiation? Semin Cancer Biol 5:229–236.
  • Schmale H, Bamberger C. 1997. A novel protein with strong homology to the tumor suppressor p53. Oncogene 15:1363–1367.
  • Shaul Y. 2000. c-abl: activation and nuclear targets. Cell Death Differ 7:10–16.
  • Sidell N, Koeffler HP. 1998. Modulation of Mr 53,000 protein with induction of differentiation of human neuroblastoma cells. Cancer Res 48:2226–2230.
  • Stiewe T, Theseling CC, Pützer BM. 2002. Transactivation-deficient Delta TAp73 inhibits p53 by direct competition for DNA binding : implications for tumorigenesis. J Biol Chem 277:14177–14185.
  • Stiewe T, Pützer BM. 2002. Role of p73 in malignancy : tumor suppressor or oncogene? Cell Death Differ 9:237–245.
  • Strano S, Fontemaggi G, Costanzo A, Rizzo MG, Monti O, Baccarini A, Del Sal G, Levrero M, Sacchi A, Oren M, Blandino G. 2002. Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem 277:18817–18826.
  • Sun XF. 2002. p73 overexpression is a prognostic factor in patients with colorectal adenocarcinoma; Clin Cancer Res 8:165–170.
  • Tannapfel A, Wasner M, Krause K, Geissler F, Katalinic A, Hauss J, Mossner J, Engeland K, Witteking C. 1999. Expression of p73 and its relation of histopathology and prognosis in hepatocellular carcinoma. J Natl Cancer Inst 91:1154–1158.
  • Thanos CD, Bowie JU. 1999. p53 family members p63 and p73 are SAM domain-containing proteins. Protein Sci 8:1708–1710.
    Direct Link:
  • van Bokhoven H, Hamel BC, Bamshad M, Sangiorgi E, Gurrieri F, Duijf PH, Vanmolkot KR, van Beusekom E, van Beersum SE, Celli J, Merkx GF, Tenconi R, Fryns JP, Verloes A, Newbury-Ecob RA, Raas-Rotschild A, Majewski F, Beemer FA, Janecke A, Chitayat D, Crisponi G, Kayserili H, Yates JR, Neri G, Brunner HG. 2001. p63 gene mutations in EEC syndrome, limb-mammary syndrome, and isolated split hand-split foot malformation suggest a genotype–phenotype correlation. Am J Hum Genet 69:481–492.
  • Versteeg R, Caron H, Cheng N, Van der Drift P, Slater R, Westerveld A, Voûte P, Delattre O, Laureys G, Van Roy N, Speleman F. 1995. 1p36: every subband a suppressor? Eur J Cancer 31A:538–541.
  • Wang X, Arooz T, Siu WY, Chiu CH, Lau A, Yamashita K, Poon RY. 2001. MDM2 and MDMX can interact differently with ARF and members of the p53 family. FEBS Lett 490:202–208.
  • Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, Andrews NC, Caput D, McKeon F. 1998. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating death-inducing and dominant negative activities. Mol Cell 2:305–316.
  • Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, Tabin C, Sharpe A, Caput D, Crum C, McKeon F. 1999. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398:714–718.
  • Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonin J, Vagner C, Bonnet H, Dikkes P, Sharpe A, McKeon F, Caput D. 2000. P73-deficient mice have neurobiological, pheromonal and inflammatory defects but lack spontaneous tumors. Nature 404:99–103.
  • Yang A, Kaghad M, Caput D, McKeon F. 2002. On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet 18:90–95.
  • Zaika AL, Kovalev S, Marchenko ND, Moll UM. 1999. Overexpression of the wild type p73 gene in breast cancer tissues and cell lines. Cancer Res 59:3257–3263.
  • Zaika A, Irwin M, Sansome C, Moll UM. 2001. Oncogenes induce and activate endogenous p73 protein. J Biol Chem 276:11310–11316.
  • Zeng X, Chen L, Jost CA, Maya R, Kelle D, Wang X, Kaelin WG, Jr., Oren M, Chen J, Lu H. 1999. MDM2 suppresses p73 function without promoting p73 degradation. Mol Cell Biol 19:3257–3266.
  • Zhu J, Jiang J, Zhou W, Chen X. 1998. The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res 58:5061–5065.
Get PDF (179K)